Cogent’s Bezuclastinib Delivers 16.5-Month PFS in Phase 3 PEAK, Earns FDA Breakthrough Status

Introduction

Cogent Biosciences Inc. (ticker: COGT), trading on the NAS exchange at $32.00 per share as of November 10, 2025, is a biotechnology company focused on developing precision therapies for genetically driven diseases. Headquartered in Waltham, Massachusetts, the firm utilizes validated biology to design targeted treatments for conditions such as systemic mastocytosis and gastrointestinal stromal tumors (GIST).

Corporate Structure

Founded in 2014, Cogent employs between 51 and 200 people across research, clinical development, commercial operations, and support functions. Key executives include:

• John Robinson, PhD, Chief Scientific Officer
• Cheryl Napier, Senior Research Project Manager
• LouAnn Cable, Senior Principal Scientist, Cell Biology
• Cole Pinnow, Chief Commercial Officer, who has over 20 years of experience in the oncology sector from Pfizer and Hospira.

The company’s collaborative structure emphasizes transparency and efficient decision-making, with multidisciplinary teams focused on advancing clinical and preclinical programs.

Biotechnology by Louis Reed

Recent Developments

On November 5, 2025, Cogent announced top-line results from its Phase 3 PEAK trial in GIST. The study reported a median progression-free survival of 16.5 months for patients receiving bezuclastinib plus sunitinib, compared to 9.2 months for those on sunitinib monotherapy. A live webcast discussing these outcomes occurred on the same day.

In October 2025, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to bezuclastinib for two indications:

• Nonadvanced systemic mastocytosis in patients previously treated with avapritinib
• Smoldering systemic mastocytosis

These designations focus on patient populations lacking an approved standard of care.

During the third quarter of 2025, Cogent reported revenue generated from collaboration milestones and maintained a significant investment in research and development. The company plans to file a New Drug Application for bezuclastinib by year-end, pending data from the APEX trial expected in December 2025.

Financial and Strategic Analysis

As of November 10, 2025, Cogent’s share price of $32.00 reflected a 115.92% increase over the past 12 months, with a trading volume of 761,502 shares. The third quarter 2025 results included milestone payments related to clinical progress and collaboration agreements, countered by ongoing research and development expenditures. The company is concentrating on advancing bezuclastinib through three registration-directed trials—PEAK, APEX, and SUMMIT—and obtaining regulatory approval. A planned New Drug Application filing by the end of 2025 illustrates a path toward potential commercialization, while pipeline diversification aims to broaden future revenue streams.

Market Position and Industry Context

Cogent operates in the precision oncology space alongside established pharmaceutical firms and emerging biotech companies. Its lead asset, bezuclastinib—a selective KIT inhibitor—addresses both systemic mastocytosis and GIST by targeting exon 17 activation loop mutations. The company’s preclinical pipeline includes an EGFR-sparing ErbB2 inhibitor designed for HER2-driven cancers. Industry trends toward targeted therapies and regulatory incentives, such as Breakthrough Therapy Designation, align with Cogent’s clinical development strategy.

tl;dr

COGT shares rose to $32.00 on November 10, 2025, reflecting a 115.92% increase year-to-date. On November 5, 2025, Phase 3 PEAK data indicated 16.5 months median progression-free survival for bezuclastinib plus sunitinib compared to 9.2 months for sunitinib alone in GIST. In October 2025, the FDA granted Breakthrough Therapy Designation for bezuclastinib in both Nonadvanced and smoldering systemic mastocytosis. Third quarter 2025 results support a New Drug Application filing by year-end, with APEX trial data anticipated in December 2025.